- Precision BioSciences Inc Extraordinary Shareholders Meeting TranscriptJan 18, 2024
- Precision BioSciences Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) TranscriptOct 25, 2023
- Precision BioSciences Inc at Stifel Tailoring Genes: Genetic Medicines Day (Virtual) TranscriptMay 30, 2023
- Precision BioSciences Inc Annual Shareholders Meeting TranscriptMay 04, 2023
- Precision BioSciences Inc at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days (Virtual) TranscriptApr 03, 2023
- Precision BioSciences Inc at HC Wainwright Cell Therapy Virtual Conference TranscriptFeb 28, 2023
- Precision BioSciences Inc at H C Wainwright Global Investment Conference (Virtual) TranscriptSep 13, 2022
- Precision BioSciences Inc Announces In Vivo Gene Editing Collaboration with Novatris TranscriptJun 22, 2022
- Precision BioSciences Inc Allogeneic CAR T Update- Conference Call TranscriptJun 08, 2022
- Precision BioSciences Inc Annual Shareholders Meeting TranscriptMay 10, 2022
- Precision BioSciences Inc at Jefferies Gene Therapy/Editing Summit (Virtual) TranscriptOct 27, 2021
- Precision BioSciences Inc PBCAR0191 Clinical Data Call TranscriptJun 04, 2021
- Precision BioSciences Inc Annual Shareholders Meeting TranscriptMay 10, 2021
- Precision BioSciences Inc Reacquires Global Rights to its Allogeneic CAR T Programs- Conference Call TranscriptApr 15, 2021
- Precision BioSciences Inc at Truist Securities Life Sciences Summit (April Series) TranscriptApr 13, 2021
- Precision BioSciences Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2021
- Cell Gene Meeting on the Mesa - Precision BioSciences TranscriptJan 08, 2021
- Precision BioSciences Inc Interim Data Results for PBCAR0191- Conference Call TranscriptDec 04, 2020
- Precision BioSciences Inc and Eli Lilly and Co In Vivo Gene Editing Collaboration - Conference Call TranscriptNov 20, 2020
Precision BioSciences Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Hello, everyone, and good afternoon, and welcome back to H.C. Wainwright's 24th Annual Global Investment Hybrid Conference. My name is Patrick Trucchio. I'm a senior healthcare analyst at H.C. Wainwright.
It's my pleasure to introduce our next presenter. I'd like to welcome Michael Amoroso, CEO; Derek Jantz, CSO; and Alan List, CMO of Precision BioSciences, a clinical-stage gene-editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies.
So maybe if we could just begin with an overview of Precision's ARCUS platform, how it's differentiated versus other approaches in the field such as CRISPR.
Yes, just a quick one, Patrick. And Wainwright, thanks for having us. We're excited to be with you. And I'm going to turn it over to our CSO and Co-Founder, Derek Jantz, for an overview on the organization.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)